Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Galbusera

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The American Journal of Pathology|April 28, 2005
In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathiesMarina Morigi, Simona Buelli, Stefania Angioletti, et al.
Frontiers in Immunology|March 24, 2022
SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet AggregationLuca Perico, Marina Morigi, Miriam Galbusera, et al.
Frontiers in Immunology|July 19, 2021
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration PlasmapheresisDiego Curtò, Federica Tomatis, Sara Gastoldi, et al.
Thrombosis and Haemostasis|February 5, 2009
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodiesElena Bresin, Sara Gastoldi, Erica Daina, et al.
Thrombosis and Haemostasis|March 1, 2005
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathiesMaria Piedad Ruiz-Torres, Federica Casiraghi, Miriam Galbusera, et al.
Pediatric Nephrology (Berlin, Germany)|November 26, 2015
Liver transplantation for aHUS: still needed in the eculizumab era?Rosanna Coppo, Roberto Bonaudo, R Licia Peruzzi, et al.
Frontiers in Medicine|November 23, 2020
Molecular Studies and an <i>ex vivo</i> Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 VariantRossella Piras, Paraskevas Iatropoulos, Elena Bresin, et al.
Frontiers in Immunology|February 27, 2023
An <i>ex vivo</i> test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndromeSara Gastoldi, Sistiana Aiello, Miriam Galbusera, et al.
Blood|July 20, 2002
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndromeGiuseppe Remuzzi, Miriam Galbusera, Marina Noris, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 28, 2017
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular ThrombosisSerena Bettoni, Miriam Galbusera, Sara Gastoldi, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The American Journal of Pathology|April 28, 2005
In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathiesMarina Morigi, Simona Buelli, Stefania Angioletti, et al.
Frontiers in Immunology|March 24, 2022
SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet AggregationLuca Perico, Marina Morigi, Miriam Galbusera, et al.
Frontiers in Immunology|July 19, 2021
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration PlasmapheresisDiego Curtò, Federica Tomatis, Sara Gastoldi, et al.
Thrombosis and Haemostasis|February 5, 2009
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodiesElena Bresin, Sara Gastoldi, Erica Daina, et al.
Thrombosis and Haemostasis|March 1, 2005
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathiesMaria Piedad Ruiz-Torres, Federica Casiraghi, Miriam Galbusera, et al.
Pediatric Nephrology (Berlin, Germany)|November 26, 2015
Liver transplantation for aHUS: still needed in the eculizumab era?Rosanna Coppo, Roberto Bonaudo, R Licia Peruzzi, et al.
Frontiers in Medicine|November 23, 2020
Molecular Studies and an <i>ex vivo</i> Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 VariantRossella Piras, Paraskevas Iatropoulos, Elena Bresin, et al.
Frontiers in Immunology|February 27, 2023
An <i>ex vivo</i> test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndromeSara Gastoldi, Sistiana Aiello, Miriam Galbusera, et al.
Blood|July 20, 2002
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndromeGiuseppe Remuzzi, Miriam Galbusera, Marina Noris, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 28, 2017
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular ThrombosisSerena Bettoni, Miriam Galbusera, Sara Gastoldi, et al.
Pageof 4